The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to ...

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The ...

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke ... However, some secondary outcome measures, such as brain damage, were not ...

Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a decades-old medication used by most hospitals in the U.S. and could hold ...

Since brain damage occurs and progresses rapidly during an acute ischemic stroke, immediate, fast-acting medical care is vital. “Today’s approval is a significant step forward and underscores ...

(npj Parkinson's Disease) Tris Pharma announced positive topline results from the ALLEVIATE-2 phase III clinical trial of investigational cebranopadol to treat moderate-to-severe acute pain after ...

Therefore, we believe that the "Tregs-microglia-neuron/neural precursor cells" axis is instrumental in mediating immune suppression and neuroprotection in the context of ischemic stroke. Given the ...